source
- Roche eyes up to $9 billion annual sales from breast cancer pill and obesity drug pipeline amid biosimilar pressureRoche reported first‑quarter earnings that showed a 5% dip in reported revenue, driven by a weaker U.S. dollar against the Swiss franc. On a constant‑currency basis, sales rose 6% to 14.7 billion S…
- Amneal to acquire biosimilar maker for $375 million upfrontAmneal Pharmaceuticals announced it will purchase a biosimilar development company, agreeing to pay $375 million in an upfront cash payment. The deal expands Amneal’s portfolio in the growing biosi…